Clinical Trial Update: A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR101 in the Treatment of Subjects With Interstitial Lung Disease [Phase 1, Phase 2]

View source ↗

Summary

This document describes an early-phase clinical trial (Phase 1/2) evaluating safety, tolerability, and preliminary efficacy of NCR101 in subjects with interstit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Interstitial Lung Disease

Drugs mentioned

• NCR101

Snippet

Sponsor: Nuwacell Biotechnologies Co., Ltd. | Conditions: Interstitial Lung Disease (ILD) | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING